Ohdan H, Yang Y G, Shimizu A, Swenson K G, Sykes M
Transplantation Biology Research Center, Surgical Service, Massachusetts General Hospital/Harvard Medical School, Boston 02129, USA.
J Clin Invest. 1999 Aug;104(3):281-90. doi: 10.1172/JCI6656.
Gal alpha 1,3Gal-reactive (Gal-reactive) antibodies are a major impediment to pig-to-human xenotransplantation. We investigated the potential to induce tolerance of anti-Gal-producing cells and prevent rejection of vascularized grafts in the combination of alpha 1,3-galactosyltransferase wild-type (GalT(+/+)) and deficient (GalT(-/-)) mice. Allogeneic (H-2 mismatched) GalT(+/+) bone marrow transplantation (BMT) to GalT(-/-) mice conditioned with a nonmyeloablative regimen, consisting of depleting CD4 and CD8 mAb's and 3 Gy whole-body irradiation and 7 Gy thymic irradiation, led to lasting multilineage H-2(bxd) GalT(+/+) + H-2(d) GalT(-/-) mixed chimerism. Induction of mixed chimerism was associated with a rapid reduction of serum anti-Gal naturally occurring antibody levels. Anti-Gal-producing cells were undetectable by 2 weeks after BMT, suggesting that anti-Gal-producing cells preexisting at the time of BMT are rapidly tolerized. Even after immunization with Gal-bearing xenogeneic cells, mixed chimeras were devoid of anti-Gal-producing cells and permanently accepted donor-type GalT(+/+) heart grafts (>150 days), whereas non-BMT control animals rejected these hearts within 1-7 days. B cells bearing receptors for Gal were completely absent from the spleens of mixed chimeras, suggesting that clonal deletion and/or receptor editing may maintain B-cell tolerance to Gal. These findings demonstrate the principle that induction of mixed hematopoietic chimerism with a potentially relevant nonmyeloablative regimen can simultaneously lead to tolerance among both T cells and Gal-reactive B cells, thus preventing vascularized xenograft rejection.
α1,3半乳糖基转移酶野生型(GalT(+/+))和缺陷型(GalT(-/-))小鼠联合使用时,α1,3半乳糖(Gal)反应性抗体(Gal反应性抗体)是猪到人的异种移植的主要障碍。我们研究了诱导抗Gal产生细胞耐受并防止血管化移植物排斥的可能性。采用非清髓性方案对GalT(-/-)小鼠进行预处理,该方案包括清除CD4和CD8单克隆抗体、3 Gy全身照射和7 Gy胸腺照射,然后将同种异体(H-2不匹配)GalT(+/+)骨髓移植(BMT)到GalT(-/-)小鼠体内,导致持久的多谱系H-2(bxd) GalT(+/+) + H-2(d) GalT(-/-)混合嵌合体形成。混合嵌合体的诱导与血清抗Gal天然抗体水平的快速降低有关。BMT后2周检测不到抗Gal产生细胞,这表明BMT时预先存在的抗Gal产生细胞迅速被耐受。即使在用含Gal的异种细胞免疫后,混合嵌合体也没有抗Gal产生细胞,并能永久接受供体类型的GalT(+/+)心脏移植物(>150天),而非BMT对照动物在1-7天内排斥这些心脏。混合嵌合体的脾脏中完全没有带有Gal受体的B细胞,这表明克隆缺失和/或受体编辑可能维持B细胞对Gal的耐受性。这些发现证明了一个原理,即采用潜在相关的非清髓性方案诱导混合造血嵌合体可同时导致T细胞和Gal反应性B细胞的耐受,从而防止血管化异种移植物排斥。